Literature DB >> 7912520

Taxol: a history of pharmaceutical development and current pharmaceutical concerns.

J D Adams1, K P Flora, B R Goldspiel, J W Wilson, S G Arbuck, R Finley.   

Abstract

Taxol, a unique diterpene anticancer compound derived from the bark of the Taxus brevifolia (Pacific yew) tree, induces cytotoxicity by a novel mechanism of action. An antimicrotubule agent, Taxol promotes the formation and stabilization of the tubulin polymer unlike other anticancer agents that induce microtubule disassembly. Because of its poor aqueous solubility, Taxol is formulated as a solution in 50% Cremophor EL and 50% dehydrated alcohol, USP. The Cremophor EL and dehydrated alcohol vehicle used in the formulation of Taxol creates some interesting challenges for its preparation and administration. The pharmaceutical concerns associated with the preparation and administration of Taxol are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7912520

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  43 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Taxol biosynthesis and molecular genetics.

Authors:  Rodney Croteau; Raymond E B Ketchum; Robert M Long; Rüdiger Kaspera; Mark R Wildung
Journal:  Phytochem Rev       Date:  2006-02       Impact factor: 5.374

3.  Development of a polymeric surgical paste formulation for taxol.

Authors:  C I Winternitz; J K Jackson; A M Oktaba; H M Burt
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

4.  Hydrotropic polymeric micelles for enhanced paclitaxel solubility: in vitro and in vivo characterization.

Authors:  Sang Cheon Lee; Kang Moo Huh; Jaehwi Lee; Yong Woo Cho; Raymond E Galinsky; Kinam Park
Journal:  Biomacromolecules       Date:  2007-01       Impact factor: 6.988

Review 5.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

6.  CD44 Signaling Mediates High Molecular Weight Hyaluronan-Induced Antihyperalgesia.

Authors:  Luiz F Ferrari; Eugen V Khomula; Dioneia Araldi; Jon D Levine
Journal:  J Neurosci       Date:  2017-11-24       Impact factor: 6.167

Review 7.  Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.

Authors:  Albert J ten Tije; Jaap Verweij; Walter J Loos; Alex Sparreboom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo.

Authors:  Cheng Jin; Haimin Li; Yong He; Min He; Ling Bai; Yunxin Cao; Wenjie Song; Kefeng Dou
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-20       Impact factor: 4.553

9.  Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells.

Authors:  Cheng Jin; Ling Bai; Hong Wu; Wenjie Song; Guozhen Guo; Kefeng Dou
Journal:  Pharm Res       Date:  2009-04-21       Impact factor: 4.200

Review 10.  Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.

Authors:  Evelina Miele; Gian Paolo Spinelli; Ermanno Miele; Federica Tomao; Silverio Tomao
Journal:  Int J Nanomedicine       Date:  2009-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.